Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2556429 | 0.90 | MEN1 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2560900 | 0.90 | KMT2A (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22337578 | 0.84 | CA12 (0.31) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4431813 | 0.79 | POLB (0.61) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8903951 | 0.76 | CYP3A4 (0.46) | POLBRAB9ASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL27542819 | 0.76 | FAAH (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL28196704 | 0.76 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27372734 | 0.76 | RAB9A (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL288566 | 0.76 | CYP3A4 (0.46) | POLBRAB9ASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL11687534 | 0.76 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113521299-B | Pyrazolopyrimidine derivative or conjugate thereof, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11767294-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | ENDOCYTE, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-113929689-B | Synthetic method of key intermediate of Lukapari | 济南悟通生物科技有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20220096646-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-03-31 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCTYE, INC. | 2010-12-23 | — | — | US | disclosed |
| WO-2010084157-A2 | MULTIFUNCTIONAL STEALTH NANOPARTICLES FOR BIOMEDICAL USE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-07-29 | — | — | WO | disclosed |
| EP-2210616-A1 | Multifunctional stealth nanoparticles for biomedical use | Centre National de la Recherche Scientifique (FR) | 2010-07-28 | — | — | EP | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-4785010-A | AGING RESISTANCE OF HUMANS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1988-11-15 | — | — | US | disclosed |
| EP-0124067-B1 | 2-(AMINOALKYL)-PYRROLE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1986-12-17 | — | — | EP | disclosed |
| EP-0124067-A1 | 2-(Aminoalkyl)-pyrrole derivatives, process for their manufacture and their use | CASSELLA Aktiengesellschaft (DE) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | CHRM2 693/4885CHRM4 1919/4885CHRM5 882/4885 |
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | CD47, PBK, GZMB | CHRM2 4862/4885CHRM4 4805/4885CHRM5 4680/4885 |
| US-11767294-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | CHRM2 463/4885CHRM4 1371/4885CHRM5 601/4885 |
| US-20220096646-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR1, SSTR4, SSTR3 | CHRM2 1605/4885CHRM4 1377/4885CHRM5 1947/4885 |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | CD44, HAVCR2, HCAR1 | CHRM2 4051/4885CHRM4 3679/4885CHRM5 4439/4885 |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | CHRM2 423/4885CHRM4 1266/4885CHRM5 540/4885 |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | CHRM2 1065/4885CHRM4 1899/4885CHRM5 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.